- RecruitingPHASE1, PHASE2
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
This study looks at new treatments for bladder cancer (and related areas) that has spread or is advanced, especially when previous treatments haven't worked well. It tests different medicines to see if they can help patients whose cancer hasn't responded to standard immune-boosting drugs.
For: Urothelial CarcinomaUnited States · Australia · Canada - RecruitingPHASE1, PHASE2
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
This study is testing new treatments for a type of bladder cancer that has spread or can't be removed, called urothelial cancer. Researchers want to see if adding new medicines to standard treatment is safe and if it helps shrink the cancer.
For: Bladder CancerUnited States · Chile · France